argenx SE (NASDAQ:ARGX) receives average price target of $540.37 from analysts

argenx SE (NASDAQ:ARGX – Get Your Free Report ) has received an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $540.37.

A number of brokerages have commented on ARGX. Stifel Nicolaus boosted their target price on argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Oppenheimer upgraded argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price for the company in a research report on Tuesday, July 23rd. Robert W. Baird upped their target price on argenx from $490.00 to $515.00 and gave the stock an “outperform” rating in a research report on Monday, July 29th. Piper Sandler upped their target price on argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. Finally, Bank of America reiterated a “buy” rating and set a $607.00 target price (up previously from $535.00) on shares of argenx in a research report on Monday. June 24.

See the latest stock report on ARGX

Institutional investors are weighing in on Argenx

Several institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new stake in shares of argenx in the second quarter valued at about $6,709,000. Creative Planning boosted its stake in argenx by 15.5% in the 2nd quarter. Creative Planning now owns 3,528 shares of the company’s stock worth $1,517,000 after acquiring an additional 474 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in argenx by 69.9% in the second quarter. Driehaus Capital Management LLC now owns 28,309 shares of the company’s stock worth $12,174,000 after purchasing an additional 11,642 shares during the last quarter. Mackenzie Financial Corp boosted its stake in argenx by 8.4% during the second quarter. Mackenzie Financial Corp now owns 2,265 shares of the company’s stock worth $974,000 after acquiring an additional 176 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in argenx by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 55,435 shares of the company’s stock worth $23,839,000. after acquiring an additional 1,048 shares in the last quarter. 60.32% of shares are held by institutional investors.

The performance of argenx shares

Shares of ARGX opened at $519.64 on Tuesday. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $540.49. The company’s 50-day moving average is $470.00, and its two-hundred-day moving average is $413.11. The company has a market cap of $30.88 billion, a price-to-earnings ratio of -91.81 and a beta of 0.64.

argenx (NASDAQ:ARGX – Get Your Free Report ) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. The business had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. In the same quarter last year, the company posted earnings per share of ($1.69). equities analysts predict that argenx will post -0.48 earnings per share for the current year.

argenx company profile

(Get a free report

argenx SE, a biotechnology company, is engaged in the development of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, the Middle East, Africa and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, or post-static postural post-tacovid syndrome. , membranous nephropathy, lupus nephropathy, hip-associated vasculitis and antibody-mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropathy, delayed graft function and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read more

Get news and reviews for argenx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for argenx and related companies with MarketBeat.com’s FREE daily email newsletter.